These results suggest that 5-HT7R expression (i) can lead to reducing cell proliferation (ii) can interfere with EGFR signaling and (iii) does not induce lethality when expressed in glial cells, underlying the interest of evaluating the role of 5-HT7R in glioma progression. Here, EGFR is linked to central nervous system cancer.